N-terminal fragment of the brain natriuretic peptide and proinflammatory cytokines in patients with coronary heart diseas

Full Text


Aim. To determine plasmic concentrations of NT-proBNP, TNFalpha and IL-6 in patients with coronary heart disease (CHD) complicated with chronic cardiac failure (CCF); to compare these parameters with hemodynamic and functional ones.
Material and methods. A total of 157 CHD patients (84.1% males, mean age 54.3 ± 6.8 years) were divided into 3 groups matched by sex and age according to the presence of CCF and left ventricular (LV) or systolic dysfunction.
Results. CCF patients with LV dysfunction or intact LV function had much higher plasmic concentrations of neurohumoral mediators than CHD patients without CCF. A plasmic NT-proBNP level over 1000 fmol/ml was associated with a 5.5-fold increase in the relative risk of LV diastolic dysfunction for CCF patients (rR 5.6; 95% CI 1.4-30.0; p = 0.0065) while an IL-6 level over 6.1 pg/ml was associated with a 9-fold increase in this risk (rR 8.9; 95% CI 2.3-35.4; p = 0.00001). Plasmic NT-proBNP and IL-6 levels went up in correlation with a CCF functional class. A plasmic level of TNFalpha correlated with anginal functional class.
Conclusion. Changes in plasmic levels of the above neuromediators are associated with changes in some LV function and functional parameters of CCF patients.


  1. Bachetti T., Ferrari R. The dynamic balance between heart function and immune activation. Eur. Heart J. 1998; 19: 681-682.
  2. Беленков Ю. Н., Агеев Ф. Т., Мареев В. Ю. Нейрогормоны и цитокины при сердечной недостаточности: новая теория старого заболевания. Сердеч. недостат. 2000; 1 (4): 135-138.
  3. Беленков Ю. Н., Оганов Р. Г. (ред.). Руководство по амбулаторно-поликлинической кардиологии. М.: Гэотар-Медиа; 2007.
  4. Gill D., Seidler T., Troughton R. W. et al. Vigorous response in plasma N-terminal pro-brain natriuretic peptide (NT-BNP) to acute myocardial infarction. Clin. Sci. (Lond.) 2004; 106: 135-139.
  5. Мазуров В. И., Столов С. В., Линецкая Н. Е. Изменение продукции некоторых провоспалительных цитокинов у больных различными вариантами ИБС. Мед. иммунол. 1999; 5: 53-65.
  6. Национальные рекомендации ВНОК и ОССН по диагностике и лечению ХСН (второй пересмотр). Сердеч. недостат. 2006; 2 (8): 1-35.
  7. Национальные рекомендации ВНОК по диагностике и лечению стабильной стенокардии (второй пересмотр). Кардиоваск. тер. и профилакт. 2008; 7 (6, прил. 4).
  8. Dutca D. P. et al. Effect of aging on neuroendocrine activation in subjects and patients in the presence and absence of heart failure with left ventricular systolic dysfunction. Am. J. Cardiol. 1996; 77: 1197-1201.
  9. Veldhuisen D. J. et al. Influence of age on neurohumoral activation and prognosis in patients with chronic heart failure. Eur. Heart J. 1998; 19: 753-760.
  10. Dibbs Z., Kurrelmeyer K., Kalra D. et al. Cytokines in heart failure: pathogenetic mechanisms and potential treatment. Proc. Assoc. Am. Physicians 1999; 111: 423-428.
  11. Hammerer-Lercher A., Ludwig W., Falkensammer G. et al. Natriuretic peptides as markers of mild forms of left ventricular dysfunction: Effects of assays on diagnostic performance of markers. Clin. Chem. 2004; 50: 1174-1183.
  12. Goedel-Meinen A., Hofmann M., Baum H. et al. Prognostic value of N-terminal-probrain natriuretic peptide - comparison of patients with diastolic and systolic heart failure. Eur. Heart J. 2004; 25 (supp. 1): 1683.
  13. Suzuki T., Yamazaki T., Yazaki Y. The role of the natriuretic peptides in the cardiovascular system. Cardiovasc. Res. 2001; 51 (3): 489-494.
  14. Harada E., Nakagawa O., Nakagawa M. et al. Induction of BNP production by interleukine-1b in myocyte-nonnmyocyte mix culture. Eur. Heart J. 1998; 19: A170.
  15. Azzawi M., Hasleton P. Tumor necrosis factor alpha and cardiovascular system: its role in cardiac allograft and heart disease. Cardiovasc. Res. 1999; 12: 850-859.
  16. Hasper D., Hummel M., Kleber F. X. et al. Systemic inflammation in patients with heart failure. Eur. Heart J. 1998; 19: 761-765.
  17. Bradham W. S., Bozkurt B., Gunasinghe H. et al. Tumour necrosis factor-alpha and myocardial remodeling in progression of heart failure: a current perspective. Cardiovasc. Res. 2002; 53: 822-830.
  18. Deswal A., Petersen N. J., Feldman A. M. et al. Cytokines and cytokine receptors in advanced heart failure: an analysis of the cytokine database from the vesnarinone trial (VEST). Circulation 2001; 103 (16): 2055-2059.
  19. Ungureanu-Longrois D., Balligand J.-L., Okada I. et al. Induction of nitric oxide syntase activity by cytokines in ventricular myocytes is necessary but not sufficient to decrease myocyte contractile responsiveness to beta-adrenergic agonist. Circ. Res. 1995; 77: 494-496.
  20. Кадагидзе З. Г. Цитокины. Практ. онкол. 2003; 4 (3): 131-139.
  21. Pfister R. et al. Use of NT-proBNP in routine testing and comparison to BNP. Eur. J. Heart Fail. 2004; 6: 289-293.
  22. Глухова Е. З., Еремеева М. В., Полякова Э. С., Бокерия Л. А. Использование предшественников натрийуретических пептидов в диагностике сердечной недостаточности ишемической этиологии до и после операции аортокоронарного шунтирования. Бюл. НЦССХ им. А. Н. Бакулева РАМН 2004; 5 (3): 146-155.
  23. Wei T., Zeng C., Chen L. et al. Systolic and diastolic heart failure are associated with different plasma levels of B-type natriuretic peptide. Int. J. Clin. Pract. 2005; 59 (8): 891-894.
  24. Wheit R. M. The role of BNP in systolic heart failure. Dimens. Crit. Care Nurs. 2005; 24 (4): 171-174.
  25. Torre-Amione G., Kapadia S., Benedict C. et al. Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the Studies of Left Ventricular Dysfunction (SOLVD). J. Am. Coll. Cardiol. 1996; 27: 1201-1206.
  26. Testa M., Yeh M., Lee P. et al. Circulating levels of cytokines and their endogenous modulators in patients with mild to severe congestive heart failure due to coronary artery disease or hypertension. J. Am. Coll. Cardiol. 1996; 28: 964-971.
  27. Munger M. A., Johnson B., Amber I. J. et al. Circulating concentrations of proinflammatory cytokines in mild or moderate heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am. J. Cardiol. 1996; 77: 723-727.
  28. Beitz F., Niebauer J. Zytokinaktivierung in der Herzinsuffizienz. J. Kardiol. 2000; 7 (12): 516-518.
  29. Nakamoto M., Shapiro J. L., Shanley P. F. et al. In vitro and in vivo protective effect of atriopeptin III on ischemic acute renal failure. J. Clin. Invest. 1987; 80: 698-705.
  30. Prabhu S. D., Chandrasekar B., Murray D. R., Freeman G. L. b-Adrenergic blockade in developing heart failure: effects on myocardial inflammatory cytokines, nitric oxide, and remodeling. Circulation 2000; 101: 2103-2109.
  31. Murray D. R., Prabhu S. D., Chandrasekar B. Chronic b-adrenergic stimulation induces myocardial proinflammatory cytokine expression. Circulation 2000; 101: 2338-2341.



Abstract: 137

Article Metrics

Metrics Loading ...


  • There are currently no refbacks.

Copyright (c) 2009 Shalaev S.V., Volkova S.Y., Shalaev S.V., Volkova S.Y.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Novoslobodskaya str 31c4., Moscow, 127005, Russian Federation

Managing Editor:


© 2018-2021 "Consilium Medicum" Publishing house

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies